Patient P-01815
Synthetic patientNBL-101 · Day 117 · 35–44 · M · baseline S09Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
13%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S09
- Day 82 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 82.
Primary contributors, last 14 days
- GI instability-15
- Inflammatory activity-15
- Toxicity+5
- Treatment adherence-3
- Nutritional resilience+2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion10.8/100
improving · -8.9 vs previous 14 d
Toxicity
Blood25.4/100
improving · -1.1 vs previous 14 d
Sleep quality
Wearable49.1/100
improving · +9.0 vs previous 14 d
Energy level
Daily log6/10
improving · +0.6 vs previous 14 d
Stress level
Daily log4/10
improving · -0.5 vs previous 14 d
Steps
Wearable4,656
improving · +1,106 vs previous 14 d
Adherence
Companion87.8 %
stable · -1.1 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards restoration · 83 from the failing basin, 23 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
Would not help
- Keep histamine lowGI +5.5 next day on high-intake days · n 22
- Keep spicy lowGI +4 next day on high-intake days · n 10
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+5.5detractor · 95%
- Spicy / capsaicin+4detractor · 62%
- Insoluble fibre+2no signal · 39%
- Simple carbohydrates+1.8no signal · 32%
- Alcohol+1.2no signal · 22%
- Dietary fat load0no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Inflammatory signalling ↓15
- WearableHRV 37 ms, trending down
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Intermediate metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.3 · butyrate capacity 59/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 36 ms
- Sleep
- 6.4 h
- Steps
- 4,296
- Resting HR
- 73 bpm
Daily log: GI score 11, nutritional resilience 62, adherence 88.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01804 | 45% | S19 | AD-05 | improved | 61 |
| P-01541 | 37% | S09 | AD-05 | no change | 43 |
| P-01377 | 32% | S11 | AD-05 | no change | 42 |
| P-01483 | 32% | S14 | AD-05 | no change | 35 |
| P-01679 | 30% | S12 | AD-05 | no change | 39 |
| P-01468 | 33% | S06 | BR-03 | no change | 41 |
| P-01350 | 32% | S19 | BR-03 | no change | 34 |
| P-01689 | 31% | S13 | BR-03 | no change | 50 |
| P-01329 | 30% | S08 | BR-03 | improved | 79 |
| P-01313 | 29% | S01 | BR-03 | improved | 32 |
| P-01430 | 44% | S05 | CR-01 | improved | 54 |
| P-01654 | 29% | S08 | CR-01 | improved | 85 |